This research was conducted by Prof. Hai Fang and team from Peking University and published in Expert Review of Vaccines, evaluates the health and economic impact of introducing the 13-valent PCV (PCV13) into immunization programs in Qinghai and Hainan. Using a decision tree-Markov model, the study simulated health benefits and lifetime costs under different vaccination strategies. The findings indicate that at current immunization coverage, PCV13 could significantly reduce disease cases and mortality, demonstrating cost-effectiveness across different pricing scenarios.
Independent and joint associations of sex and birth order with non‑national immunization program vaccine coverage among Chinese children: a cross-sectional analysis
This research conducted by Prof. Xiaolin Xu and team from Zhejiang University, was published in the International Journal for Equity in Health. Based on a 2022 survey in Zhejiang and Henan provinces, the study analyzed the independent and joint associations of sex and birth order with non-National Immunization Program (non-NIP) vaccine coverage among Chinese children aged 1–6. The results showed that birth order was an important factor influencing vaccination, with the lowest coverage observed among later-born girls, particularly third or later-born daughters.